Publish date:

Jim Cramer's Stop Trading! Biotech Works

Airgas is also worth a look, he says.

The biotech sector should be bought by investors looking for upside, Jim Cramer said Thursday on

CNBC

's "Stop Trading!" segment.

Following a three-year bear market, names such as

Celgene

(CELG) - Get Report

,

Gilead

(GILD) - Get Report

and

Cephalon

(CEPH)

are worth a look, he said.

"As the economy slows, you want to own biotech," Cramer said. He also said he could now get behind the

Biotech HOLDRs

TST Recommends

(BBH) - Get Report

exchange-traded fund.

Cramer had positive comments on chemicals and air companies such as

Airgas

(ARG)

. There's "an incredible bull market in air," he said.

At the time of publication, Cramer had no positions in stocks mentioned.

Jim Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for

Action Alerts PLUS. Watch Cramer on "Mad Money" weeknights on CNBC. Click

here to order Cramer's latest book, "Mad Money: Watch TV, Get Rich," click

here to order his book, "Real Money: Sane Investing in an Insane World," click

here to get his second book, "You Got Screwed!" and click

here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by

clicking here.

TheStreet.com has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from TheStreet.com.